GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » Gross Margin %

Orion Infusions (DHA:ORIONINFU) Gross Margin % : 40.68% (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Orion Infusions Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Orion Infusions's Gross Profit for the three months ended in Dec. 2024 was BDT79.3 Mil. Orion Infusions's Revenue for the three months ended in Dec. 2024 was BDT195.0 Mil. Therefore, Orion Infusions's Gross Margin % for the quarter that ended in Dec. 2024 was 40.68%.


The historical rank and industry rank for Orion Infusions's Gross Margin % or its related term are showing as below:

DHA:ORIONINFU' s Gross Margin % Range Over the Past 10 Years
Min: 39.4   Med: 40.38   Max: 41.19
Current: 41.19


During the past 13 years, the highest Gross Margin % of Orion Infusions was 41.19%. The lowest was 39.40%. And the median was 40.38%.

DHA:ORIONINFU's Gross Margin % is ranked worse than
62.72% of 963 companies
in the Drug Manufacturers industry
Industry Median: 47.4 vs DHA:ORIONINFU: 41.19

Orion Infusions had a gross margin of 40.68% for the quarter that ended in Dec. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Orion Infusions was 0.00% per year.


Orion Infusions Gross Margin % Historical Data

The historical data trend for Orion Infusions's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions Gross Margin % Chart

Orion Infusions Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.73 40.94 41.08 40.41 40.43

Orion Infusions Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.02 40.21 42.89 41.17 40.68

Competitive Comparison of Orion Infusions's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Orion Infusions's Gross Margin % falls into.



Orion Infusions Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Orion Infusions's Gross Margin for the fiscal year that ended in Jun. 2024 is calculated as

Gross Margin % (A: Jun. 2024 )=Gross Profit (A: Jun. 2024 ) / Revenue (A: Jun. 2024 )
=334.6 / 827.416
=(Revenue - Cost of Goods Sold) / Revenue
=(827.416 - 492.862) / 827.416
=40.43 %

Orion Infusions's Gross Margin for the quarter that ended in Dec. 2024 is calculated as


Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=79.3 / 195.047
=(Revenue - Cost of Goods Sold) / Revenue
=(195.047 - 115.704) / 195.047
=40.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Orion Infusions  (DHA:ORIONINFU) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Orion Infusions had a gross margin of 40.68% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Orion Infusions Gross Margin % Related Terms

Thank you for viewing the detailed overview of Orion Infusions's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions Business Description

Traded in Other Exchanges
N/A
Address
153-154 Tejgaon I/A, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions Headlines

No Headlines